ASKA Pharmaceutical Holdings Co Ltd
TSE:4886

Watchlist Manager
ASKA Pharmaceutical Holdings Co Ltd Logo
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Watchlist
Price: 2 070 JPY -1.33% Market Closed
Market Cap: 58.6B JPY
Have any thoughts about
ASKA Pharmaceutical Holdings Co Ltd?
Write Note

ASKA Pharmaceutical Holdings Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ASKA Pharmaceutical Holdings Co Ltd
Additional Paid In Capital Peer Comparison

Comparables:
4502
4568
4578
4519
4503

Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Additional Paid In Capital
ÂĄ1.8B
CAGR 3-Years
26%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Additional Paid In Capital
ÂĄ1.8T
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
42%
Daiichi Sankyo Co Ltd
TSE:4568
Additional Paid In Capital
ÂĄ2.7B
CAGR 3-Years
N/A
CAGR 5-Years
-51%
CAGR 10-Years
-31%
Otsuka Holdings Co Ltd
TSE:4578
Additional Paid In Capital
ÂĄ505.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Chugai Pharmaceutical Co Ltd
TSE:4519
Additional Paid In Capital
ÂĄ69.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%
Astellas Pharma Inc
TSE:4503
Additional Paid In Capital
ÂĄ182.6B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%

See Also

What is ASKA Pharmaceutical Holdings Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
1.8B JPY

Based on the financial report for Mar 31, 2024, ASKA Pharmaceutical Holdings Co Ltd's Additional Paid In Capital amounts to 1.8B JPY.

What is ASKA Pharmaceutical Holdings Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
15%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for ASKA Pharmaceutical Holdings Co Ltd have been 26% over the past three years , 15% over the past five years .

Back to Top